Advisers to the U.S. Food and Drug Administration on Thursday recommended the agency approve Pfizer’s respiratory syncytial virus, or RSV, vaccine for pregnant women, despite concerns about premature births identified during clinical trials.

Commenting on the FDA’s recommendation of Pfizer’s RSV vaccine, Dr. Peter McCullough, a cardiologist, told The Defender:

“This product represents an unprecedented attempt to vaccinate mothers for no benefit to them and only theoretical efficacy in babies. In the trial, less than 2% of infants at any time point contracted RSV, which is easily treatable with nebulizers.

“Pregnancies should not be threatened with novel vaccines for uncommon and low-risk infantile illnesses.

“Widespread use of this reactogenic vaccine can be expected to cause fetal loss in some unfortunate women. A single case of pregnancy termination would not be worth the population being vaccinated.”

https://childrenshealthdefense.org/defender/fda-recommends-pfizer-rsv-vaccine-pregnant-women/?